FILTER

Refine your search with the following facets to narrow down your results.

8 Current news of Karo Bio

Karo Bio Enters Collaboration with Pfizer to Discover and Develop Innovative Drugs for Autoimmune Diseases

03-Jan-2012 - Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive right to ...

autoimmune diseases

Changes in Management Of Karo Bio AB

19-Aug-2011 - Karo Bio AB announced that Jens Kristensen, Chief Medical Officer and Vice President Preclinical Development and Regulatory affairs, leaves his position. Acting President and CEO Per Bengtsson will temporarily assume management responsibility for clinical development and regulatory affairs until ...

Karo Bio: Karo Bio’s CEO, Fredrik Lindgren, Leaves

26-May-2011 - Karo Bio AB communicated that Fredrik Lindgren will leave his position as CEO of the company. A new CEO will be appointed by the board at the board meeting on May 24, 2011.“After discussions, conditions for continued co-operation are too limited, which the board regrets”, says Göran Wessman, ...

Karo Bio Announces Successful Phase II Study with Eprotirome in Combination with Statin

05-Aug-2008 - Karo Bio has successfully completed a 12 week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on statin treatment. Data show that eprotirome induced a statistically significant and clinically relevant lowering of ...

blood lipids cardiovascular diseases cholesterol +3

Karo Bio announces Merck has entered clinical development with estrogen receptor compound

14-Sep-2006 - Karo Bio announced that an estrogen receptor compound discovered as part of its research collaboration with Merck & Co., Inc. has entered Phase I clinical development. The collaboration with Merck began in November 1997 with the objective of developing new treatments targeting estrogen ...

milestone payments research collaborations

Karo Bio and Wyeth extend research collaboration

09-Aug-2006 - Karo Bio announced that Wyeth and Karo Bio extended their atherosclerosis collaboration for an additional year until August 31, 2007. The primary objective of the extension is to characterize back up compounds and to further evaluate additional clinical possibilities by targeting LXR. The ...

atherosclerosis cholesterol inflammation +3

Karo Bio and Wyeth Extend Research Collaboration

17-Aug-2005 - Wyeth and Karo Bio have agreed to extend the research term of their atherosclerosis collaboration for an additional year until August 31, 2006 with the intention of selecting candidate drugs for development. Karo Bio entered into a three year research collaboration with Wyeth Pharmaceuticals in ...

atherosclerosis cholesterol diseases +2

Clinical Trials Initiated and Significant Milestone Reached in the Collaboration Between Karo Bio and Merck & Co., Inc.

26-Jan-2005 - Clinical trials have been initiated for the most advanced compound in the drug discovery and development collaboration between Merck & Co., Inc. and Karo Bio. The advancement of this compound, in clinical development to address an important unmet clinical need, has triggered a significant ...

clinical trials